These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 28025920

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB.
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
    Wielage RC, Perk S, Campbell NL, Klein TM, Posta LM, Yuran T, Klein RW, Ng DB.
    J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
    [Abstract] [Full Text] [Related]

  • 5. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB, Espinosa R, Johnson SJ, Walker D, Gooch K.
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J, Maman K, Neine ME, Briquet B, Odeyemi IA, Hakimi Z, Garnham A, Aballéa S.
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of New Medications and $4 Generic Programs on Overactive Bladder Treatment Among Older Adults in the United States, 2000-2015.
    Kinlaw AC, Jonsson Funk M, Conover MM, Pate V, Markland AD, Wu JM.
    Med Care; 2018 Feb; 56(2):162-170. PubMed ID: 29287033
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.
    Minhas R, Tadrous M, Elterman D, Gomes T.
    Neurourol Urodyn; 2018 Jun; 37(5):1693-1700. PubMed ID: 29682790
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.
    Armstrong EP, Malone DC, Bui CN.
    J Med Econ; 2012 Jun; 15 Suppl 1():35-44. PubMed ID: 22998646
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
    Angulo JC, Sánchez-Ballester F, Peral C, Rejas J, Ramos J, Snedecor SJ, Sudharshan L, Liu S, Luo X.
    Actas Urol Esp; 2016 Oct; 40(8):513-22. PubMed ID: 26988624
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
    Krunal Vishavadia KV, Sandip Solanki SS, Hiren Prajapati HP, Madhu Sharma MS.
    Urologiia; 2023 May; (2):66-72. PubMed ID: 37401707
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
    Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Aguado-Jodar A, Ruíz-Torrejón A.
    Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.